Prescription Event Monitoring study of Hapid Advance in the Osteoarthritis and joints patients.

A prospective, observational prescription event monitoring study to evaluate the prescription pattern of HAPID ADVANCE marketed by Wockhardt Limited in Indian population. - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2026/01/101547

Enrollment

3500

Registered

2026-01-19

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M150- Primary generalized (osteo)arthritis

Interventions

Intervention1: Hapid Advance: HAPID ADVANCE Tablet of Wockhardt containing Calcium, Boscurin (A combination of Boswellia serrata extract and Curcuma longa extract), Vitamin C, Native collagen type I

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patient age 18 years or above 18 years. 2 willing to participate in the study and provide inform consent. 3. Patients diagnosed with bone and joint disease.

Exclusion criteria

Exclusion criteria: 1. patients with history of hypersensitivity of drug and same class of drug.

Design outcomes

Primary

Measure	Time frame
VAS ScoreTimepoint: at Pretreatment Day 0 and post treatment at 12th weeks	—

Secondary

Measure	Time frame
Adverse EventTimepoint: at Pretreatment Day 0 and post treatment at 12th weeks or any other time of point during the Study period reported telephonically.	—

Countries

India

Contacts

Public ContactDr Khokan Debnath

Wockhardt

AChatterjee@wockhardt.com02226596407

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026